The DIS3 antibody targets a protein encoded by the DIS3 gene, a key component of the RNA exosome complex involved in RNA processing, surveillance, and degradation. DIS3 possesses 3'-5' exoribonuclease activity, critical for maintaining RNA homeostasis by degrading aberrant mRNAs and processing ribosomal RNAs. It plays roles in cell cycle regulation, genomic stability, and embryonic development. Dysregulation or mutations in DIS3 are strongly linked to cancers, particularly multiple myeloma, where DIS3 mutations occur in ~10-15% of cases and often correlate with poor prognosis. DIS3 antibodies are widely used to study the protein's expression, localization, and function in cellular and disease models. Researchers employ these antibodies in techniques like Western blotting, immunofluorescence, and immunohistochemistry to investigate DIS3's involvement in RNA quality control, its interaction with exosome subunits, and its impact on oncogenic pathways. Additionally, they help identify DIS3 mutations and assess their effects on protein stability or enzymatic activity in clinical samples. By enabling mechanistic studies on DIS3 loss or dysfunction, these antibodies contribute to understanding RNA metabolism defects, genome instability, and cancer progression. Their utility in co-immunoprecipitation and functional assays further positions DIS3 as a potential therapeutic target. Thus, DIS3 antibodies serve as vital tools in both fundamental RNA biology and translational research focused on hematologic malignancies.